Latigo Biotherapeutics priced its IPO to raise about $345.6 million for a non-opioid pain pipeline focused on the Nav1.8 channel pathway, part of a broader 2026 pattern of upsized biotech offerings. The company positioned the round as fuel for advancing multiple candidates tied to its ion-channel mechanism. In a separate IPO, Blossomhill Therapeutics launched a $150 million offering to fund next-generation macrocyclic cancer inhibitors, including development aimed at EGFR-mutant non-small-cell lung cancer. The IPO was upsized from initial plans, continuing the market’s willingness to pay for differentiated modalities. Meanwhile, broader public equity activity remains hot: one report says four biotechs raised more than $1.2B collectively in a strong IPO run, underlining sustained investor appetite for late-stage and platform-driven stories.